



Moatassem Abdallah
Co-Founder
Founder
Director &
CTO




Caroline Clevenger
Co-Founder
Strategy &
Sustainable Integration



Shahryar Monghasemi
Co-Founder
Engineering
and Development



John Tolva
Urban Data
Specialist



Business Commute Optimization System

Business Commute Optimization System (BCOS) is designed to motivate and incentivize healthier lifestyles and environmentally friendly commute solutions by identifying customized, convenient, and economic commute plans for each employee in a business or multiple businesses that are closely located. The system has a website and mobile apps where commuters can report their commute information and needs to receive recommended commute plans. Commuters can receive multiple recommended commute plans where they can accept the plans that fit their needs. Additionally, BCOS calculates monetary incentives for commuters to incentivize them to follow recommended commute plans that minimize greenhouse gas and air pollution emissions as well as commuting time and cost. Finally, BCOS is designed to generate reports on employers' commute footprint and best strategies for reducing negative impacts, such as public transit pass, carpooling, and/or parking cash-out.

FOUNDERS



Carson Bruns



Jesse Butterfield

HYPRSKN

HYPRSKN (formerly CHROMAPRAXIS) technologies augment human capabilities through microscopic skin implants. Our adaptive, color-changing, in-skin pigments serve a number of application domains:


- "Magic" tattoo inks unlock a new category of re-writable body art that morphs as the lighting changes.
- Intradermal UV sensors warn users when they need sun protection by appearing only at high exposure levels.
- Activatable biopsy site markers help dermatologists prevent wrong-site surgery in skin cancer patients.
- UV-responsive skin markings provide secure authentication of user information ranging from private memberships to vaccine history.



Robert M. Scribner
CEO, BOD



Mark Borden PhD
CSO, BOD



Paul Mountford PhD
Dir. of R&D, BOD



Robert Scribner
Dir. of Operations

RESPIROGEN

Respirogen™ Micro-Oxygen (RMO) technology has been demonstrated to increase the oxygen saturation of the blood in hypoxia without the use of the lungs. This creates a new and novel strategy to augment oxygen management in lung compromise for emergency response and in ventilator protocols. RMO will provide capillary oxygen to cardiac arrest trauma patients, to hypoxic lung compromised patients in ARDS, in emergency resuscitation and transport, premature infants with lung disorders, and other clinical situations where hypoxia causes organ damage.



Lise St. Denis

Chatizy

Chatizy provides the ultimate tool for the hybrid workforce and customer-centric brands overwhelmed by live video chats and frustrated by the lack of response. Chatizy filters and organizes real-time chat feeds, helps facilitators, and enables workflows to continue the conversations offline. We use AI to provide insights for facilitators/sponsors and to close the loop for participants to answer questions and capture valuable feedback.





Pandemic Hyper-Accelerator for Science and Technology Teams



Tassa Saldi, PhD
CEO



Alfonso Garrido-Lecca, PhD
Science Director



Erika Lasda, PhD
Laboratory Operations



Patrick Gonzales
Technology Director



Rolando Marriquin
Business Development



Marko Melnick, PhD
Head of AI and Software



Gonzalo Villaran
Business Development Latin America



Santiago Garrido-Lecca
Finance and Operations



TUMI Genomics creates innovative solutions that facilitate rapid, high-throughput pathogen detection. We provide diagnostic products and services to healthcare and agriculture industries utilizing both our Point-of-Care DxGlow platform (under review by FDA) and pathogen detection services in TUMI Labs. TUMI Genomics is committed to rigorous, creative and ethical science with a strong focus on customer service.



tumigenomics.com



www.linkedin.com/company/respirogen



@tumigenomics



@tumigenomics @tumiagriculture



Vesicle Therapeutics is a biotechnology startup company focused on developing engineered extracellular vesicle therapeutics and vaccines. Vesicle Therapeutics is developing a platform technology called Gectosomes that encapsulate therapeutic enzymes, nucleic acids, and gene editing complex to the intracellular space. We aim to develop targeted biologics for the treatment of specific human diseases.



Xuedong Liu
Founder, President



Donna Peak
Co-founder, COO



Gan Zhang, Ph.D.
Vice President



Jared Crain
Counsel



Camila Uzategui



John Hergert

Vitro3D

Vitro3D is revolutionizing 3D printing for the life sciences industry by bringing printers to the patient point of-care with a beachhead market in the dental industry. We have a proprietary technology focused on microscale control over material properties in 3D using both standard Digital Light Projection and cuttingedge volumetric 3D printing.



Jennifer Howard



Rachel Anderson



vitro3d.com



www.linkedin.com/company/vitro3d